Development and scale up of a fully continuous flow synthesis of 2-aminothiazole-4-acetic acid
- 3 November 2026
- journal article
- Published by Royal Society of Chemistry (RSC) in Reaction Chemistry & Engineering
- Vol. 11 (11) , 2906-2912
Abstract
We report an efficient continuous flow synthesis of 2-aminothiazole-4-acetic acid, as a key pharmaceutical intermediate of mirabegron, cefotiam. The production capacity of 670 g h −1 exhibits excellent potential for industrial implementation.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LQN26B020008)
- Science Research Foundation of Zhejiang Province (2026XMGD040)
- Zhejiang University of Technology (KYY-HX-20220471)
- National Natural Science Foundation of China (22178066)
- National Natural Science Foundation of China (22478082)
This publication has 26 references indexed in Scilit:
- Prophylactic effect of cefotiam against postoperative infection: Systematic review and meta-analysisJournal of Infection and Chemotherapy, 2026
- Liquid–solid mass transfer in micropacked bed reactors with immiscible liquid–liquid two-phase flowChinese Journal of Chemical Engineering, 2025
- Continuous Flow Technology Enabling PhotochemistryAdvanced Synthesis & Catalysis, 2025
- Distinct Conformations of Mirabegron Determined by MicroEDAdvanced Science, 2023
- Multistep continuous flow synthesis of ErlotinibChinese Chemical Letters, 2023
- Synthesis, characterization and molecular docking studies of highly functionalized and biologically active derivatives of 2-aminothiazoleJournal of Molecular Structure, 2022
- Mirabegron: A Review in Overactive Bladder SyndromeDrugs, 2018
- The Hitchhiker’s Guide to Flow ChemistryChemical Reviews, 2017
- Synthesis and in vitro kinetic evaluation of N-thiazolylacetamido monoquaternary pyridinium oximes as reactivators of sarin, O-ethylsarin and VX inhibited human acetylcholinesterase (hAChE)Bioorganic & Medicinal Chemistry, 2015
- Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazolesEuropean Journal of Medicinal Chemistry, 2013